Yesterday, the Senate Finance Committee held its first hearing on the Transatlantic Trade and Investment Partnership (TTIP), a comprehensive free trade agreement that the U.S. and European Union have begun negotiating.
Yesterday, I had the opportunity to speak at a conference of regulatory and compliance professionals – those who are dedicated to ensuring that regulation works.
Millions of prescriptions are filled every year in the United States and the patients who depend on these medications must have confidence in their safety and authenticity.
A survey commissioned earlier this year by PhRMA shows 86 percent of Americans believe developing cures for more forms of cancer should be one of the top national health priorities.
Until this morning, on the rare occasions when I thought of Omaha, Nebraska, I would conjure up images of Warren Buffett, thick juicy steaks, a clean quiet Midwestern city and friendly, laid-back folks, not necessarily in that order.
I learned today that I was not inaccurate, all of the above is true, but my picture was far from complete.
Alzheimer’s has proven to be a stubborn, puzzling and perhaps even symbolic disease. In recent years, it has emerged as one of our greatest tests of biopharmaceutical science because of the disease’s vast and growing impact on the health of our aging population and the viability of our health care system.
Today, PhRMA will be hosting a stakeholder action group meeting with the National Council for Prescription Drug Programs (NCPDP) called “Maximizing Prescription Quality Through ePrescribing.” NCPDP is a non-for-profit, American National Standards Institute (ANSI) certified standards development organization.
How can we continue to advance cancer research and improve patient outcomes in an era of cost containment? The issue was recently highlighted in a New York Magazine article that only provided part of the story on cancer progress and cost containment. Last week I had the opportunity to tackle this question as part of a roundtable that convened leaders from across the cancer community.
Today, I’ll be speaking to state-wide leaders in California regarding the state’s fight against obesity.
This year, biopharmaceutical companies committed to transforming how their clinical research can be used to advance innovation for patients through careful sharing of clinical trial data with independent researchers.
More than 30 million Americans suffer from rare diseases – conditions that are classified as such because they affect fewer than 200,000 people in the United States.
Earlier this month, Bill Chin announced on this blog that PhRMA will be hosting a forum along with the Alzheimer’s Association and the Alzheimer’s Drug Discovery Foundation on Wednesday, October 23rd.
Tuesday began Medicare Part D Open Enrollment. With the program still going strong 10 years after it was enacted, Part D represents a significant milestone for patients.
The cultural anthropologist Margaret Mead once said, “Never doubt that a small group of thoughtful, committed citizens can change the world. Indeed, it is the only thing that ever has.”
As the 12 countries negotiating the Trans-Pacific Partnership (TPP) approach the finish line after years of hard work on an ambitious agreement, there remains quite a bit of work left to be done. Now that all the low hanging fruit has been picked, the most difficult issues remain to be finalized. Not surprisingly, intellectual property (IP) is one of those issues
Across the nation, millions of seniors and disabled Americans have access to innovative medicines through the Medicare prescription drug program (Part D). This year, we’re celebrating the 10-year anniversary of the program’s enactment, as well as taking note of the important feedback provided by those individuals who rely on it.
Every day, our industry strives to connect patients, families and advocates from across the globe who share our common goals of preventing diseases, improving health and saving lives. Those strong voices of innovators and stakeholders working tirelessly to address pressing medical challenges, and many medical breakthroughs wouldn’t be possible today or in the future without them.
In the last 20 years, the Prescription Drug User Fee Act (PDUFA) has resulted in timelier patient access to more than 1,500 new drugs and biologics, decreasing review times for these treatments by more than 60 percent.
We’re excited to host a guest blog post by Steve Pasierb, the passionate CEO of The Partnership at Drugfree.org. We’ve been longtime partners with The Partnership, and Steve’s blog will be the first of regular updates about what’s new in The Partnership at Drugfree.org’s world.